84 related articles for article (PubMed ID: 9489350)
21. Hormone replacement therapy in postmenopausal women.
Yasui T; Uemura H; Takikawa M; Irahara M
J Med Invest; 2003 Aug; 50(3-4):136-45. PubMed ID: 13678382
[TBL] [Abstract][Full Text] [Related]
22. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
23. Continuation of hormone replacement therapy in Slovenia: a prospective, randomized, controlled trial--1-year follow-up.
Franić D; Verdenik I; Meden-Vrtovec H; Svab I
Maturitas; 2006 May; 54(2):110-8. PubMed ID: 16293377
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of the hematochemical parameters and bone mineral density of women in physiological menopause treated with hormone replacement therapy with nomegestrol acetate and surgical menopause treated with estrogen replacement. Part II].
Savoca S; D'Agosta S; Lombardo G
Minerva Ginecol; 2007 Jun; 59(3):215-22. PubMed ID: 17576400
[TBL] [Abstract][Full Text] [Related]
25. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
[TBL] [Abstract][Full Text] [Related]
26. Spanish post-menopausal women's viewpoints on hormone therapy.
Castelo-Branco C; Ferrer J; Palacios S; Cornago S; Peralta S
Maturitas; 2007 Apr; 56(4):420-8. PubMed ID: 17174045
[TBL] [Abstract][Full Text] [Related]
27. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women.
Ichikawa J; Sumino H; Ichikawa S; Ozaki M
Am J Hypertens; 2006 Jul; 19(7):744-9. PubMed ID: 16814131
[TBL] [Abstract][Full Text] [Related]
28. Two routes of hormonal replacement therapy in symptomatic menopausal women after kidney transplantation.
Pietrzak B; Wielgos M; Kaminski P; Bobrowska K
Neuro Endocrinol Lett; 2006 Jun; 27(3):387-91. PubMed ID: 16816826
[TBL] [Abstract][Full Text] [Related]
29. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women.
Gambacciani M; Ciaponi M; Cappagli B; Genazzani AR
Am J Obstet Gynecol; 2001 Nov; 185(5):1180-5. PubMed ID: 11717654
[TBL] [Abstract][Full Text] [Related]
30. Menopausal symptoms and knowledge towards daily life and hormone replacement therapy among menopausal women in Bangkok.
Chaopotong P; Titapant V; Boriboonhirunsarn D
J Med Assoc Thai; 2005 Dec; 88(12):1768-74. PubMed ID: 16518972
[TBL] [Abstract][Full Text] [Related]
31. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen.
Foidart JM; Faustmann T
Gynecol Endocrinol; 2007 Dec; 23(12):692-9. PubMed ID: 18075844
[TBL] [Abstract][Full Text] [Related]
32. Moderate dosage estrogen-androgen therapy improves continuation rates in postmenopausal women: impact of the WHI reports.
Gambrell RD; Natrajan PK
Climacteric; 2006 Jun; 9(3):224-33. PubMed ID: 16766436
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
34. Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen.
Ettinger B; Pressman A; Bradley C
Menopause; 1998; 5(3):152-6. PubMed ID: 9774760
[TBL] [Abstract][Full Text] [Related]
35. Hormone replacement therapy use and menopausal symptoms among women participating in a behavioral lifestyle intervention.
Boraz MA; Simkin-Silverman LR; Wing RR; Meilahn EN; Kuller LH
Prev Med; 2001 Aug; 33(2 Pt 1):108-14. PubMed ID: 11493043
[TBL] [Abstract][Full Text] [Related]
36. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.
Olsson HL; Ingvar C; Bladström A
Cancer; 2003 Mar; 97(6):1387-92. PubMed ID: 12627501
[TBL] [Abstract][Full Text] [Related]
37. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
[TBL] [Abstract][Full Text] [Related]
38. [Evaluation of the risk-benefit ratio of hormonal replacement therapy for menopause and susceptible elements in maximizing compliance].
Lopes P; Mensier A
J Gynecol Obstet Biol Reprod (Paris); 1996; 25(7):694-8. PubMed ID: 8991903
[TBL] [Abstract][Full Text] [Related]
39. Menopausal depression: comparison of hormone replacement therapy and hormone replacement therapy plus fluoxetine.
Liu P; He FF; Bai WP; Yu Q; Shi W; Wu YY; He DJ; Xiao JH; Zheng Y; Liao QP
Chin Med J (Engl); 2004 Feb; 117(2):189-94. PubMed ID: 14975200
[TBL] [Abstract][Full Text] [Related]
40. Use of HRT and the subsequent risk of cancer.
Beral V; Banks E; Reeves G; Appleby P
J Epidemiol Biostat; 1999; 4(3):191-210; discussion 210-5. PubMed ID: 10695959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
